Compare AR & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AR | SNN |
|---|---|---|
| Founded | 2002 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Industrial Specialties |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 12.3B |
| IPO Year | 2013 | 2002 |
| Metric | AR | SNN |
|---|---|---|
| Price | $37.12 | $30.30 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 22 | 6 |
| Target Price | ★ $50.18 | $33.19 |
| AVG Volume (30 Days) | ★ 4.1M | 1.5M |
| Earning Date | 10-28-2026 | 08-04-2026 |
| Dividend Yield | N/A | ★ 2.50% |
| EPS Growth | ★ 1027.78 | N/A |
| EPS | ★ 3.81 | N/A |
| Revenue | ★ $5,275,823,000.00 | N/A |
| Revenue This Year | $30.12 | $3.93 |
| Revenue Next Year | $1.29 | $4.98 |
| P/E Ratio | ★ $9.67 | $64.97 |
| Revenue Growth | ★ 21.97 | N/A |
| 52 Week Low | $31.15 | $26.30 |
| 52 Week High | $45.75 | $37.09 |
| Indicator | AR | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 51.02 |
| Support Level | $35.41 | $29.22 |
| Resistance Level | $38.26 | $31.32 |
| Average True Range (ATR) | 1.35 | 0.61 |
| MACD | -0.29 | -0.16 |
| Stochastic Oscillator | 20.45 | 20.39 |
Antero Resources is an exploration and production firm whose operations represent a pure play in the Marcellus Shale, located in northern West Virginia. The company started in 2002 as an E&P focused on the Barnett Shale (Fort Worth, Texas). Antero redefined itself in Appalachia's Marcellus Shale in 2005. In 2012, shortly before Antero's 2013 IPO, Antero Midstream Partners was formed to handle the company's rapidly growing gas volumes. In 2026, the firm narrowed its focus further by selling its Ohio Utica assets and using the proceeds to acquire additional Marcellus acreage from HG Energy. Just over half of its production and earning power is tied to natural gas, with the remainder mostly NGLs, where it holds a leading position, and some crude oil.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.